

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – March 24, 2010

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania
(State or other jurisdiction
of incorporation)

1-8036
(Commission File Number)

23-1210010
(IRS Employer
Identification No.)

101 Gordon Drive, PO Box 645, Lionville, PA
(Address of principal executive offices)

19341-0645
(Zip Code)

610-594-3319
(Registrant's telephone number, including area code)

Not Applicable
(Former name or address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 7.01 Regulation FD Disclosure

On March 17, 2010, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William J. Federici, Chief Financial Officer, will present at the Barclays Capital 2010 Global Healthcare Conference in Miami, FL on March 24, 2010 at 2:30 PM ET.

A copy of the press release is attached hereto as Exhibit 99.1. A copy of the Company’s presentation from the conference will be available for 30 days through the Investors link at the Company’s website, <http://www.westpharma.com>, and is also attached hereto as Exhibit 99.2. Both Exhibits are incorporated herein by reference.

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financials Statement and Exhibits

(d) Exhibits

Exhibit #	Description
99.1	West Pharmaceutical Services, Inc. Press Release, dated March 17, 2010.
99.2	West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

March 24, 2010

EXHIBIT INDEX

Description

99.1 West Pharmaceutical Services, Inc. Press Release, dated March 17, 2010.

99.2 West Pharmaceutical Services, Inc. Corporate Overview (Investor Presentation).



Contacts:
West Pharmaceutical Services, Inc.
Michael A. Anderson
Vice President and Treasurer
(610) 594-3345

Investors and Financial Media:
Westwicke Partners
John Woolford/Stefan Loren
(443) 213-0506/0507

West to Present at Barclays Investor Conference

LIONVILLE, Pa., March 17, 2010 -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer, and William Federici, Chief Financial Officer, will attend the Barclays Capital 2010 Global Healthcare Conference in Miami, FL. Management will present an overview of West's business and outlook on Wednesday, March 24, 2010 at 2:30 PM ET.

A copy of the corporate presentation document as well as a live audio webcast of the presentations will be posted on the investor link of the Company's website at www.westpharma.com.

About West

West is a global manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. Headquartered in Lionville, Pennsylvania, West supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at www.westpharma.com.



Donald E. Morel
Chairman and Chief Executive Officer

William J. Federici
Vice President and Chief Financial Officer

Investor Relations Contact:
Michael A. Anderson
Vice President and Treasurer
mike.anderson@westpharma.com

Barclays 2010 Global Healthcare Conference
Miami, FL
March 24, 2010

NYSE: WST
westpharma.com



Forward Looking Statements

Delivering Innovative Solutions

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates and forecasts. Statements that are not historical facts, including statements that are preceded by, followed by, or that include, words such as "estimate," "expect," "intend," "believe," "plan," "anticipate" and other words and terms of similar meaning are forward-looking statements. West's estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect our current perspective on existing trends and information.

Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. These statements are subject to known or unknown risks or uncertainties, and therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you consider forward-looking statements. A non-exclusive list of important factors that may affect future results may be found in West's filings with the Securities and Exchange Commission, including our annual report on Form 10-K and our periodic reports on Form 10-Q and Form 8-K.

You should evaluate any statement in light of these important factors.

- For more than eighty years, a global leader in the development and manufacturing of components and systems for injectable drug delivery
 - Vial closure systems
 - Prefillable syringe components
 - Components for diagnostics
 - Devices and device sub-assemblies
 - Safety and administration systems
- Market capitalization \$1.4 billion
- Diverse, stable customer base
- Global footprint



West Pharmaceutical Services Today



6,000 employees worldwide

● 32 plants in 10 countries

● 34 sales offices

● 7 technical centers

- **Challenges:**
 - Adverse effects of pension expense, currency effects
 - Recession impacted customer order patterns
 - Tighter cost, working capital and inventory management
 - Some major programs delayed or cancelled
 - First half sales declines
- **Full year revenues grew by 3.5 % excluding currency**
 - H1N1-related sales growth
 - Customer cyclical inventory adjustments moderating
 - Year end backlog at highest level in recent quarters
- **Pharma mergers and consolidation**
- **Key developments:**
 - Validated Daikyo Crystal Zenith 1ml single cavity manufacturing cell
 - Four cavity cell installed late Q4; commercial production should start Q3 2010
 - Plastef acquisition completed
 - Officially opened China Plastics facility
 - Announced plans to restructure and re-align operating segments in Q4

2009 Revenue Growth vs. Prior Year Period by Business Segment

	Excludes Impact of Foreign Currency				
	Q1	Q2	Q3	Q4	Full Year
Pharm Systems	-2.7%	1.6%	7.8%	18.7%	5.9%
Tech Group	-3.4%	-1.1%	-6.4%	-3.1%	-3.5%
Consolidated	-2.9%	0.7%	4.3%	13.2%	3.5%

Consolidated Fourth Quarter Operating Results


(\$ millions)



- Ex-Currency, Growth was:
 - \$ 32.2 Revenue (13.2%)
 - \$ 10.2 Gross Profit (14.7%)
 - \$ 2.2 Adjusted Operating Profit (7.9%)
- Currency translation added:
 - \$ 16.3 Revenue
 - \$ 4.1 Gross Profit
 - \$ 1.8 Operating Profit
- Major Changes:
 - H1N1-related, prefillable component, and metal seal sales
 - Lower relative SG&A costs

Sales and Income from Continuing Operations

(\$ in millions)



- Global economic conditions remain soft, but show signs of improvement
- Analyzing future impact of US healthcare legislation
- Global pharmaceutical revenue growth projected to be 4-6% (per IMS) on **modest unit growth**
 - North America growth projected at 4.5 - 5.5%
 - Europe growth moderate 2-4%
 - Emerging economies should grow > 10% (India, China, Brazil)
- Return to more normalized order patterns
- Further consolidation - e.g Teva - Ratiopharm



2010 Expectations and Milestones

Delivering Innovative Solutions

- Revenue Growth: 3% to 5% (excluding currency)
 - Consolidated revenues: \$1,090 - \$1,120 million¹
- Consolidated Gross Margin of 30.5%
- Adjusted Diluted² EPS: \$2.19 to \$2.39
- Validate new Daikyo CZ production cell
- Secure first Daikyo CZ commercial program
- Break ground on China rubber facility

1. *The principal currency assumption in these estimates is for the translation of the Euro at \$1.40 for 2010.*

2. *“Adjusted Diluted EPS” refers to earnings per share excluding expected restructuring charges of between \$0.02 and \$0.04 per share.*

Pharmaceutical Packaging Systems

(How drugs are contained)

Primary Container Solutions

- Small volume parenteral packaging
- Large volume parenteral packaging
- Prefillable syringe components
- Disposable medical device components
- Diagnostic, dental, veterinary packaging

Pharmaceutical Delivery Systems

(How drugs are administered)

Administration Systems

- Safety systems (NovaGuard, Eris)
- Reconstitution systems - MediMop
- CZ prefillable syringe systems
- Advanced Injection Systems (Confidose)
- Tech Group Contract Manufacturing



Five-Year Growth Opportunity

Delivering Innovative Solutions

Pharmaceutical Packaging Systems
Primary Container Solutions

\$1.5 billion market for components with unit growth 0% to 8% per year, depending on product and therapeutic segment

Strategic Planning Goals:

- Projected 2014 sales of \$1.0 billion
- Projected 2014 Operating margin: 20%

Pharmaceutical Delivery Systems
Administration Systems

\$2 billion combined markets for safety, prefilled and auto-injectors, with unit growth 6-12%, depending on product and therapeutic segment

Strategic Planning Goals:

- Projected 2014 sales of \$0.6 billion
- Projected 2014 Operating margin: 20%

Consolidated 2014 Planning Objectives

- 2014 Sales: \$1.6 billion
- 2014 Operating Margin: 19%
- 2014 Consolidated ROIC: 17%

- Demographics
- Growth in Biologics & Vaccines
- Requirement for easy, safe, accurate dosing
- Combination product growth
- Generic growth
- Increasing global access to advanced healthcare



West supplies sophisticated packaging systems for the top 20 biologic drugs (by sales) currently on the market.

Category	Key Customers	Projected Growth
Diabetes	  	8 - 10%
Oncology	  	6 - 8%
Vaccines	  	4 - 6%
Autoimmune	    	6 - 8%



Our Growth Strategy

Delivering Innovative Solutions

Pharmaceutical Packaging Systems

(How drugs are contained)

Primary Container Solutions

- Therapeutic segment focus
- Generate incremental value per unit
- Leverage changing regulatory environment
- Optimize manufacturing productivity
- Strategic acquisitions
- Geographic expansion
 - China
 - India

West's Competitive Advantages:

- Unmatched expertise in drug - material interactions
- Market leader in packaging for biologics
- Protected IP: Proprietary materials and processing technology - Drug Master File (DMF) 1546
- Regulatory barriers to entry:
US NDAs and ANDAs require proof of stability
- Global technical support

Revenue and Margin Opportunity



Packaging

Delivery



PROPRIETARY PRODUCTS



Westar® RU



éris™



NovaGuard™



Westar® RS



Mix2Vial®



Standard Components



Disposable Device Components



Consumer Products

Pharmaceutical Packaging Systems

Primary Container Solutions

- Therapeutic segment focus
- Generate incremental value per unit
- Leverage changing regulatory environment
- Optimize manufacturing productivity
- Strategic acquisitions
- Geographic expansion
- China
- India

Pharmaceutical Delivery Systems

Administration Systems

- **Concentrate on systems for unmet market needs**
- **Build market share in multi-component systems for drug administration utilizing Daikyo CZ as a platform technology**
- **Production supported by existing design, multi-material molding, and assembly capabilities**
- **Expand through innovation and strategic technology acquisitions**



MixJect®



Daikyo Crystal Zenith®



**ConfiDose®
Auto-
injector**



Vial2Bag™



Mix2Vial®



**éris™
Safety Needle
(fixed-ratio syringe)**



**NovaGuard™ Safety
Needle Device
(luer-lock syringe)**

- **Pharmaceutical Packaging Systems**
 - Organic growth (on average) of 3-5% per year
 - Margin expansion through improved operating efficiency, product mix
 - Capital investments targeted at enhanced quality and value
- **Pharmaceutical Delivery Systems**
 - Deliver the potential of Daikyo CZ products
 - Increase healthcare-consumable contract manufacturing revenue
 - Grow proprietary safety and delivery system businesses
- **Financial discipline**
 - Operating cash flow: Discretionary SG&A, R&D and capital spending that are supported by revenue growth.
 - Deliver returns on invested capital (“ROIC”) that regularly exceed weighted average cost of capital (“WACC”).
 - Align incentives with financial performance and value creation

- **A valuable franchise**
 - Substantial market share
 - Proprietary technology
 - Diversified Customer Base
 - Global footprint
- **Positioned to grow**
 - Strength in new product pipeline
 - Preferred products for biologics
- **With the financial strength to invest**
 - Reliable operating cash flow
 - Balance sheet strength
- **Led by an experienced management team**
 - Aligned incentives



Injectable Container Solutions



Prefillable Syringe Systems



Safety and Administration Systems



Advanced Injection Systems



Donald E. Morel
Chairman and Chief Executive Officer

William J. Federici
Vice President and Chief Financial Officer

Investor Relations Contact:
Michael A. Anderson
Vice President and Treasurer
mike.anderson@westpharma.com

Barclays 2010 Global Healthcare Conference
Miami, FL
March 24, 2010

NYSE: WST
westpharma.com

